Provided by Tiger Trade Technology Pte. Ltd.

Celcuity Inc

65.78
-5.4700-7.68%
Post-market: 67.001.22+1.85%19:50 EDT
Volume:3.16M
Turnover:212.54M
Market Cap:3.21B
PE:-15.22
High:73.51
Open:70.52
Low:64.15
Close:71.25
52wk High:151.02
52wk Low:45.03
Shares:48.77M
Float Shares:29.72M
Volume Ratio:1.89
T/O Rate:10.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3223
EPS(LYR):-3.7900
ROE:-1433.70%
ROA:-25.78%
PB:-250.99
PE(LYR):-17.36

Loading ...

VistaGen Q1 Revenue Rises on Licensing Agreement Expiration

Reuters
·
Aug 14

Stifel Nicolaus Reaffirms Their Buy Rating on Celcuity (CELC)

TIPRANKS
·
Aug 14

Wells Fargo Reaffirms Their Buy Rating on Celcuity (CELC)

TIPRANKS
·
Aug 14

Celcuity Price Target Cut to $140.00/Share from $157.00 by Needham

Dow Jones
·
Aug 14

U.S. Research Roundup-Cisco, Fox Corp, Target

Reuters
·
Aug 14

Celcuity Inc. : Jefferies Raises Target Price to $163 from $153

THOMSON REUTERS
·
Aug 14

Celcuity Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Celcuity Posts Narrower-than-Expected Loss as R&D Costs Decreased

Reuters
·
Aug 14

Celcuity Q2 Adjusted Loss Widens

MT Newswires Live
·
Aug 14

Celcuity Q2 Adj. EPS $(1.07) Beats $(1.17) Estimate

Benzinga Earnings
·
Aug 14

Celcuity Q2 Adjusted EPS USD -1.07 Vs. IBES Estimate USD -1.16

Reuters
·
Aug 14

Celcuity Q2 Adjusted EPS USD -1.07 VS. Ibes Estimate USD -1.16

THOMSON REUTERS
·
Aug 14

Press Release: Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
Aug 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 13

Celcuity to Report Q2 Results, Host Webcast Call

Reuters
·
Aug 06

Celcuity announces NCCN recommendation for Revtorpyk combination

TIPRANKS
·
Jul 30

Celcuity Says NCCN Guidelines Add Newly FDA-approved Revtorpyk for Advanced Hr+/her2- Breast Cancer

Reuters
·
Jul 30

Celcuity - FDA Approves Revtorpyk for Hr+/Her2- Advanced Breast Cancer Without Pik3CA Mutation on July 14, 2026

THOMSON REUTERS
·
Jul 30

Newly FDA-Approved Revtorpyk™ (Gedatolisib) Included in the National Comprehensive Cancer Network® (Nccn®) Clinical Practice Guidelines for Hr+/Her2- Locally Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Jul 30

Celcuity - Revtorpyk Expected to be Commercially Available in U.S. in Late Q3 2026

THOMSON REUTERS
·
Jul 30